Merck & Co., Inc. (MRK) Wins FDA Nod for WELIREG + LENVIMA in ccRCC
Merck received FDA approval for WELIREG (belzutifan) plus LENVIMA (lenvatinib) to treat adults with advanced ccRCC after PD—1/PD—L1 therapy, based on Phase 3 LITESPARK—011 showing PFS benefit vs cabozantinib; OS did not reach statistical significance.Material DetailsContext by AI AnalystThis is a l…